RU2568608C2 - Твердые формы n-(4-(7-азабицикло[2.2.1]гептан-7-ил)-2-(трифторметил)фенил)-4-оксо-5-(трифторметил)-1,4-дигидрохинолин-3-карбоксамида - Google Patents

Твердые формы n-(4-(7-азабицикло[2.2.1]гептан-7-ил)-2-(трифторметил)фенил)-4-оксо-5-(трифторметил)-1,4-дигидрохинолин-3-карбоксамида Download PDF

Info

Publication number: RU2568608C2
Authority: RU; Russia
Prior art keywords: peak; degrees; region; hcl; disease
Prior art date: 2009-10-23

Application number

RU2012121168/04A

Other languages

English (en)

Russian (ru)

Other versions

RU2012121168A (ru

Inventor

Бэйли Чжан

Мариуш Кравец

Брайан ЛУИЗИ

Алес МЕДЕК

Original Assignee

Вертекс Фармасьютикалз Инкорпорейтед

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-23

Filing date

2010-10-21

Publication date

2015-11-20

2010-10-21 Application filed by Вертекс Фармасьютикалз Инкорпорейтед filed Critical Вертекс Фармасьютикалз Инкорпорейтед

2013-11-27 Publication of RU2012121168A publication Critical patent/RU2012121168A/ru

2015-11-20 Application granted granted Critical

2015-11-20 Publication of RU2568608C2 publication Critical patent/RU2568608C2/ru

Links

239000007787 solid Substances 0.000 title abstract description 71
238000000034 method Methods 0.000 claims abstract description 101
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 86
201000010099 disease Diseases 0.000 claims abstract description 75
230000000694 effects Effects 0.000 claims abstract description 59
230000035772 mutation Effects 0.000 claims abstract description 45
QYLPFQBPOBAQSP-UHFFFAOYSA-N n-[4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl]-4-oxo-5-(trifluoromethyl)-1h-quinoline-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=C2C(=O)C(C(=O)NC3=CC=C(C=C3C(F)(F)F)N3C4CCC3CC4)=CNC2=C1 QYLPFQBPOBAQSP-UHFFFAOYSA-N 0.000 claims abstract description 18
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
239000012472 biological sample Substances 0.000 claims abstract description 10
201000003883 Cystic fibrosis Diseases 0.000 claims description 62
210000004027 cell Anatomy 0.000 claims description 53
208000011580 syndromic disease Diseases 0.000 claims description 40
238000000634 powder X-ray diffraction Methods 0.000 claims description 38
201000009266 primary ciliary dyskinesia Diseases 0.000 claims description 33
208000025678 Ciliary Motility disease Diseases 0.000 claims description 27
208000006673 asthma Diseases 0.000 claims description 27
239000013078 crystal Substances 0.000 claims description 22
230000007812 deficiency Effects 0.000 claims description 22
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims description 21
206010006451 bronchitis Diseases 0.000 claims description 21
206010033645 Pancreatitis Diseases 0.000 claims description 20
201000010064 diabetes insipidus Diseases 0.000 claims description 20
108090000623 proteins and genes Proteins 0.000 claims description 20
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 19
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 19
208000001132 Osteoporosis Diseases 0.000 claims description 14
210000000988 bone and bone Anatomy 0.000 claims description 14
230000001965 increasing effect Effects 0.000 claims description 14
206010006458 Bronchitis chronic Diseases 0.000 claims description 13
208000007451 chronic bronchitis Diseases 0.000 claims description 13
206010014561 Emphysema Diseases 0.000 claims description 12
238000009825 accumulation Methods 0.000 claims description 11
230000007547 defect Effects 0.000 claims description 11
238000000806 fluorine-19 nuclear magnetic resonance spectrum Methods 0.000 claims description 11
210000001835 viscera Anatomy 0.000 claims description 11
206010010356 Congenital anomaly Diseases 0.000 claims description 10
206010058271 Hyperexplexia Diseases 0.000 claims description 10
208000019693 Lung disease Diseases 0.000 claims description 10
230000035508 accumulation Effects 0.000 claims description 10
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims description 10
206010012601 diabetes mellitus Diseases 0.000 claims description 10
206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims description 9
206010010774 Constipation Diseases 0.000 claims description 9
208000003556 Dry Eye Syndromes Diseases 0.000 claims description 9
206010013774 Dry eye Diseases 0.000 claims description 9
208000015439 Lysosomal storage disease Diseases 0.000 claims description 9
208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims description 9
238000012545 processing Methods 0.000 claims description 9
208000029725 Metabolic bone disease Diseases 0.000 claims description 8
206010049088 Osteopenia Diseases 0.000 claims description 8
208000035467 Pancreatic insufficiency Diseases 0.000 claims description 8
208000021386 Sjogren Syndrome Diseases 0.000 claims description 8
239000002671 adjuvant Substances 0.000 claims description 8
230000002146 bilateral effect Effects 0.000 claims description 8
230000001886 ciliary effect Effects 0.000 claims description 8
150000002632 lipids Chemical class 0.000 claims description 8
239000000779 smoke Substances 0.000 claims description 8
208000024827 Alzheimer disease Diseases 0.000 claims description 7
102100032187 Androgen receptor Human genes 0.000 claims description 7
206010002961 Aplasia Diseases 0.000 claims description 7
206010062264 Congenital hyperthyroidism Diseases 0.000 claims description 7
208000029323 Congenital myotonia Diseases 0.000 claims description 7
208000024940 Dent disease Diseases 0.000 claims description 7
206010013883 Dwarfism Diseases 0.000 claims description 7
208000033981 Hereditary haemochromatosis Diseases 0.000 claims description 7
101000775732 Homo sapiens Androgen receptor Proteins 0.000 claims description 7
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims description 7
206010051125 Hypofibrinogenaemia Diseases 0.000 claims description 7
208000000038 Hypoparathyroidism Diseases 0.000 claims description 7
102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 7
208000007466 Male Infertility Diseases 0.000 claims description 7
208000002678 Mucopolysaccharidoses Diseases 0.000 claims description 7
208000010316 Myotonia congenita Diseases 0.000 claims description 7
206010068871 Myotonic dystrophy Diseases 0.000 claims description 7
208000012902 Nervous system disease Diseases 0.000 claims description 7
208000025966 Neurological disease Diseases 0.000 claims description 7
208000018737 Parkinson disease Diseases 0.000 claims description 7
108091000054 Prion Proteins 0.000 claims description 7
201000005660 Protein C Deficiency Diseases 0.000 claims description 7
206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 7
208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 7
208000004622 abetalipoproteinemia Diseases 0.000 claims description 7
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
208000015532 congenital bilateral absence of vas deferens Diseases 0.000 claims description 7
206010015037 epilepsy Diseases 0.000 claims description 7
201000001386 familial hypercholesterolemia Diseases 0.000 claims description 7
208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 claims description 7
201000001441 melanoma Diseases 0.000 claims description 7
206010028093 mucopolysaccharidosis Diseases 0.000 claims description 7
108010040003 polyglutamine Proteins 0.000 claims description 7
229920000155 polyglutamine Polymers 0.000 claims description 7
230000000306 recurrent effect Effects 0.000 claims description 7
230000002441 reversible effect Effects 0.000 claims description 7
201000009890 sinusitis Diseases 0.000 claims description 7
208000009575 Angelman syndrome Diseases 0.000 claims description 6
206010003591 Ataxia Diseases 0.000 claims description 6
102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims description 6
208000014644 Brain disease Diseases 0.000 claims description 6
208000032274 Encephalopathy Diseases 0.000 claims description 6
208000023105 Huntington disease Diseases 0.000 claims description 6
206010060378 Hyperinsulinaemia Diseases 0.000 claims description 6
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
208000008955 Mucolipidoses Diseases 0.000 claims description 6
206010072928 Mucolipidosis type II Diseases 0.000 claims description 6
208000021811 Sandhoff disease Diseases 0.000 claims description 6
208000022292 Tay-Sachs disease Diseases 0.000 claims description 6
208000012770 hereditary angioedema type 1 Diseases 0.000 claims description 6
230000003451 hyperinsulinaemic effect Effects 0.000 claims description 6
201000008980 hyperinsulinism Diseases 0.000 claims description 6
208000019423 liver disease Diseases 0.000 claims description 6
208000020460 mucolipidosis II alpha/beta Diseases 0.000 claims description 6
208000000638 myeloperoxidase deficiency Diseases 0.000 claims description 6
230000002988 nephrogenic effect Effects 0.000 claims description 6
230000004770 neurodegeneration Effects 0.000 claims description 6
208000015122 neurodegenerative disease Diseases 0.000 claims description 6
208000006386 Bone Resorption Diseases 0.000 claims description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 5
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 5
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 5
208000025237 Polyendocrinopathy Diseases 0.000 claims description 5
230000024279 bone resorption Effects 0.000 claims description 5
239000011575 calcium Substances 0.000 claims description 5
229910052791 calcium Inorganic materials 0.000 claims description 5
230000003247 decreasing effect Effects 0.000 claims description 5
230000008021 deposition Effects 0.000 claims description 5
230000007613 environmental effect Effects 0.000 claims description 5
230000002132 lysosomal effect Effects 0.000 claims description 5
230000001537 neural effect Effects 0.000 claims description 5
201000002212 progressive supranuclear palsy Diseases 0.000 claims description 5
102100034452 Alternative prion protein Human genes 0.000 claims description 4
208000000668 Chronic Pancreatitis Diseases 0.000 claims description 4
208000024720 Fabry Disease Diseases 0.000 claims description 4
208000019683 Gorham-Stout disease Diseases 0.000 claims description 4
208000003892 Kartagener syndrome Diseases 0.000 claims description 4
206010033649 Pancreatitis chronic Diseases 0.000 claims description 4
210000004081 cilia Anatomy 0.000 claims description 4
208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 4
230000011164 ossification Effects 0.000 claims description 4
230000000750 progressive effect Effects 0.000 claims description 4
230000020978 protein processing Effects 0.000 claims description 4
208000005139 Hereditary Angioedema Types I and II Diseases 0.000 claims description 3
206010028980 Neoplasm Diseases 0.000 claims description 3
206010030113 Oedema Diseases 0.000 claims description 3
206010033647 Pancreatitis acute Diseases 0.000 claims description 3
201000003229 acute pancreatitis Diseases 0.000 claims description 3
206010003246 arthritis Diseases 0.000 claims description 3
230000008468 bone growth Effects 0.000 claims description 3
230000010478 bone regeneration Effects 0.000 claims description 3
201000011510 cancer Diseases 0.000 claims description 3
210000001215 vagina Anatomy 0.000 claims description 3
206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
208000028782 Hereditary disease Diseases 0.000 claims description 2
208000027157 chronic rhinosinusitis Diseases 0.000 claims description 2
230000015271 coagulation Effects 0.000 claims description 2
238000005345 coagulation Methods 0.000 claims description 2
230000002496 gastric effect Effects 0.000 claims description 2
230000036210 malignancy Effects 0.000 claims description 2
201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
102000005962 receptors Human genes 0.000 claims 4
108020003175 receptors Proteins 0.000 claims 4
102000029797 Prion Human genes 0.000 claims 3
206010003694 Atrophy Diseases 0.000 claims 1
208000020084 Bone disease Diseases 0.000 claims 1
241001598984 Bromius obscurus Species 0.000 claims 1
208000007984 Female Infertility Diseases 0.000 claims 1
206010021928 Infertility female Diseases 0.000 claims 1
208000033868 Lysosomal disease Diseases 0.000 claims 1
206010056886 Mucopolysaccharidosis I Diseases 0.000 claims 1
BIVQBWSIGJFXLF-UHFFFAOYSA-N PPM-18 Chemical compound C=1C(=O)C2=CC=CC=C2C(=O)C=1NC(=O)C1=CC=CC=C1 BIVQBWSIGJFXLF-UHFFFAOYSA-N 0.000 claims 1
206010037660 Pyrexia Diseases 0.000 claims 1
208000034189 Sclerosis Diseases 0.000 claims 1
206010048327 Supranuclear palsy Diseases 0.000 claims 1
230000037444 atrophy Effects 0.000 claims 1
230000020764 fibrinolysis Effects 0.000 claims 1
230000008439 repair process Effects 0.000 claims 1
210000004291 uterus Anatomy 0.000 claims 1
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 abstract description 101
239000000126 substance Substances 0.000 abstract description 12
230000004071 biological effect Effects 0.000 abstract description 2
102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 abstract 2
239000000203 mixture Substances 0.000 description 112
102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 99
150000001875 compounds Chemical class 0.000 description 92
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 46
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
239000000523 sample Substances 0.000 description 45
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 43
239000003795 chemical substances by application Substances 0.000 description 38
238000002360 preparation method Methods 0.000 description 38
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 31
239000011541 reaction mixture Substances 0.000 description 31
JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 30
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 29
108091006146 Channels Proteins 0.000 description 27
239000000243 solution Substances 0.000 description 27
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 26
210000004379 membrane Anatomy 0.000 description 25
239000012528 membrane Substances 0.000 description 25
238000003756 stirring Methods 0.000 description 25
108020001823 ΔF508-CFTR Proteins 0.000 description 25
238000005481 NMR spectroscopy Methods 0.000 description 23
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
239000000725 suspension Substances 0.000 description 21
230000006870 function Effects 0.000 description 20
238000001228 spectrum Methods 0.000 description 20
230000032258 transport Effects 0.000 description 20
101000907783 Homo sapiens Cystic fibrosis transmembrane conductance regulator Proteins 0.000 description 17
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
238000006243 chemical reaction Methods 0.000 description 17
102000056427 human CFTR Human genes 0.000 description 17
239000000843 powder Substances 0.000 description 17
235000019439 ethyl acetate Nutrition 0.000 description 16
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
239000002904 solvent Substances 0.000 description 15
238000000576 coating method Methods 0.000 description 14
239000003814 drug Substances 0.000 description 14
YDSLNLXECXVMMY-UHFFFAOYSA-N 7-[4-nitro-3-(trifluoromethyl)phenyl]-7-azabicyclo[2.2.1]heptane Chemical compound C1=C(C(F)(F)F)C([N+](=O)[O-])=CC=C1N1C2CCC1CC2 YDSLNLXECXVMMY-UHFFFAOYSA-N 0.000 description 13
238000010521 absorption reaction Methods 0.000 description 13
WAEYWIDTDWJDJA-UHFFFAOYSA-N 4-oxo-5-(trifluoromethyl)-1h-quinoline-3-carboxylic acid Chemical compound C1=CC(C(F)(F)F)=C2C(=O)C(C(=O)O)=CNC2=C1 WAEYWIDTDWJDJA-UHFFFAOYSA-N 0.000 description 12
JQHCKZLQJDVZPH-UHFFFAOYSA-N 7-azabicyclo[2.2.1]heptane;hydrochloride Chemical compound [Cl-].C1CC2CCC1[NH2+]2 JQHCKZLQJDVZPH-UHFFFAOYSA-N 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
229910052757 nitrogen Inorganic materials 0.000 description 12
239000012044 organic layer Substances 0.000 description 12
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
230000002829 reductive effect Effects 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
-1 bicarbonate anions Chemical class 0.000 description 11
210000000981 epithelium Anatomy 0.000 description 11
239000012530 fluid Substances 0.000 description 11
239000010410 layer Substances 0.000 description 11
239000002244 precipitate Substances 0.000 description 11
230000005855 radiation Effects 0.000 description 11
239000011734 sodium Substances 0.000 description 11
ZRVMLMPILZRXTI-UHFFFAOYSA-N 8-chloro-4-oxo-5-(trifluoromethyl)-1h-quinoline-3-carboxylic acid Chemical compound C1=CC(C(F)(F)F)=C2C(=O)C(C(=O)O)=CNC2=C1Cl ZRVMLMPILZRXTI-UHFFFAOYSA-N 0.000 description 10
150000001450 anions Chemical class 0.000 description 10
238000001816 cooling Methods 0.000 description 10
230000002950 deficient Effects 0.000 description 10
238000001914 filtration Methods 0.000 description 10
238000002329 infrared spectrum Methods 0.000 description 10
230000007246 mechanism Effects 0.000 description 10
235000018102 proteins Nutrition 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
229940124597 therapeutic agent Drugs 0.000 description 10
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
206010012735 Diarrhoea Diseases 0.000 description 9
239000007995 HEPES buffer Substances 0.000 description 9
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
208000035475 disorder Diseases 0.000 description 9
230000003993 interaction Effects 0.000 description 9
210000003097 mucus Anatomy 0.000 description 9
201000008383 nephritis Diseases 0.000 description 9
239000012299 nitrogen atmosphere Substances 0.000 description 9
230000003287 optical effect Effects 0.000 description 9
239000000546 pharmaceutical excipient Substances 0.000 description 9
230000003389 potentiating effect Effects 0.000 description 9
PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 8
108700028369 Alleles Proteins 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
210000000170 cell membrane Anatomy 0.000 description 8
239000002552 dosage form Substances 0.000 description 8
HZKKQOCNNKDBRA-UHFFFAOYSA-N ethyl 8-chloro-4-oxo-5-(trifluoromethyl)-1h-quinoline-3-carboxylate Chemical compound C1=CC(C(F)(F)F)=C2C(=O)C(C(=O)OCC)=CNC2=C1Cl HZKKQOCNNKDBRA-UHFFFAOYSA-N 0.000 description 8
239000000463 material Substances 0.000 description 8
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 8
229920001223 polyethylene glycol Polymers 0.000 description 8
235000002639 sodium chloride Nutrition 0.000 description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
238000002441 X-ray diffraction Methods 0.000 description 7
239000011248 coating agent Substances 0.000 description 7
239000000945 filler Substances 0.000 description 7
239000000706 filtrate Substances 0.000 description 7
239000012634 fragment Substances 0.000 description 7
239000007788 liquid Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
230000028327 secretion Effects 0.000 description 7
238000002411 thermogravimetry Methods 0.000 description 7
GIFDDEUMMLLKIL-UHFFFAOYSA-N 4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)aniline Chemical compound C1=C(C(F)(F)F)C(N)=CC=C1N1C2CCC1CC2 GIFDDEUMMLLKIL-UHFFFAOYSA-N 0.000 description 6
OIFIAKRKSKMURW-UHFFFAOYSA-N 4-(7-azoniabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)aniline;chloride Chemical compound Cl.C1=C(C(F)(F)F)C(N)=CC=C1N1C2CCC1CC2 OIFIAKRKSKMURW-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
108010078791 Carrier Proteins Proteins 0.000 description 6
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
241000124008 Mammalia Species 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
229910052799 carbon Inorganic materials 0.000 description 6
238000004113 cell culture Methods 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
GCRDMRZCDJJIGQ-UHFFFAOYSA-N diethyl 2-[[2-chloro-5-(trifluoromethyl)anilino]methylidene]propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)=CNC1=CC(C(F)(F)F)=CC=C1Cl GCRDMRZCDJJIGQ-UHFFFAOYSA-N 0.000 description 6
238000001938 differential scanning calorimetry curve Methods 0.000 description 6
239000003937 drug carrier Substances 0.000 description 6
239000000975 dye Substances 0.000 description 6
239000012065 filter cake Substances 0.000 description 6
238000010438 heat treatment Methods 0.000 description 6
230000001771 impaired effect Effects 0.000 description 6
150000002500 ions Chemical class 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000002609 medium Substances 0.000 description 6
238000010992 reflux Methods 0.000 description 6
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
238000004922 13C solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 5
IMLXLGZJLAOKJN-UHFFFAOYSA-N 4-aminocyclohexan-1-ol Chemical compound NC1CCC(O)CC1 IMLXLGZJLAOKJN-UHFFFAOYSA-N 0.000 description 5
WMQOSURXFLBTPC-UHFFFAOYSA-N 4-fluoro-1-nitro-2-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1C(F)(F)F WMQOSURXFLBTPC-UHFFFAOYSA-N 0.000 description 5
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 5
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 5
108010067035 Pancrelipase Proteins 0.000 description 5
239000002775 capsule Substances 0.000 description 5
230000034994 death Effects 0.000 description 5
231100000517 death Toxicity 0.000 description 5
229910001873 dinitrogen Inorganic materials 0.000 description 5
235000019441 ethanol Nutrition 0.000 description 5
MNVOYAYCMYYYTO-UHFFFAOYSA-N ethyl 4-oxo-5-(trifluoromethyl)-1h-quinoline-3-carboxylate Chemical compound C1=CC(C(F)(F)F)=C2C(=O)C(C(=O)OCC)=CNC2=C1 MNVOYAYCMYYYTO-UHFFFAOYSA-N 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
229910052731 fluorine Inorganic materials 0.000 description 5
239000011737 fluorine Substances 0.000 description 5
229910052739 hydrogen Inorganic materials 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
239000008101 lactose Substances 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
239000006187 pill Substances 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
230000003248 secreting effect Effects 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000007909 solid dosage form Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
239000003826 tablet Substances 0.000 description 5
DQARDWKWPIRJEH-UHFFFAOYSA-N tert-butyl n-(4-hydroxycyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCC(O)CC1 DQARDWKWPIRJEH-UHFFFAOYSA-N 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
239000001993 wax Substances 0.000 description 5
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 4
108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 4
108091006515 Anion channels Proteins 0.000 description 4
102000037829 Anion channels Human genes 0.000 description 4
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 4
208000000059 Dyspnea Diseases 0.000 description 4
206010013975 Dyspnoeas Diseases 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
102000004310 Ion Channels Human genes 0.000 description 4
108090000862 Ion Channels Proteins 0.000 description 4
XSTRZZXVGQMKLM-LJGSYFOKSA-N N[C@H]1CC[C@H](CS(O)(=O)=O)CC1 Chemical compound N[C@H]1CC[C@H](CS(O)(=O)=O)CC1 XSTRZZXVGQMKLM-LJGSYFOKSA-N 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
238000009835 boiling Methods 0.000 description 4
229940124630 bronchodilator Drugs 0.000 description 4
239000006172 buffering agent Substances 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
239000012043 crude product Substances 0.000 description 4
238000000113 differential scanning calorimetry Methods 0.000 description 4
229940079593 drug Drugs 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
239000008103 glucose Substances 0.000 description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
230000035876 healing Effects 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
238000005984 hydrogenation reaction Methods 0.000 description 4
239000003701 inert diluent Substances 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
229940090044 injection Drugs 0.000 description 4
238000009434 installation Methods 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
208000023504 respiratory system disease Diseases 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
OOUGLTULBSNHNF-UHFFFAOYSA-N 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(ON=2)C=2C(=CC=CC=2)F)=C1 OOUGLTULBSNHNF-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102000003837 Epithelial Sodium Channels Human genes 0.000 description 3
108090000140 Epithelial Sodium Channels Proteins 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 3
206010031243 Osteogenesis imperfecta Diseases 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
230000000172 allergic effect Effects 0.000 description 3
239000008346 aqueous phase Substances 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
208000010668 atopic eczema Diseases 0.000 description 3
210000003050 axon Anatomy 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000008859 change Effects 0.000 description 3
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 3
229940125904 compound 1 Drugs 0.000 description 3
239000010949 copper Substances 0.000 description 3
108010040974 cystic fibrosis transmembrane conductance regulator delta F508 Proteins 0.000 description 3
229910003460 diamond Inorganic materials 0.000 description 3
239000010432 diamond Substances 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
206010013781 dry mouth Diseases 0.000 description 3
230000004064 dysfunction Effects 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000012091 fetal bovine serum Substances 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 3
239000011521 glass Substances 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000033001 locomotion Effects 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
229960001855 mannitol Drugs 0.000 description 3
230000000420 mucociliary effect Effects 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000002685 pulmonary effect Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
210000000664 rectum Anatomy 0.000 description 3
238000002310 reflectometry Methods 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000000241 respiratory effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
239000008247 solid mixture Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
238000001757 thermogravimetry curve Methods 0.000 description 3
229960000707 tobramycin Drugs 0.000 description 3
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 3
238000003828 vacuum filtration Methods 0.000 description 3
238000005406 washing Methods 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical compound C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
VKTTYIXIDXWHKW-UHFFFAOYSA-N 2-chloro-5-(trifluoromethyl)aniline Chemical compound NC1=CC(C(F)(F)F)=CC=C1Cl VKTTYIXIDXWHKW-UHFFFAOYSA-N 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical class N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
102000011045 Chloride Channels Human genes 0.000 description 2
108010062745 Chloride Channels Proteins 0.000 description 2
206010010904 Convulsion Diseases 0.000 description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
XRHVZWWRFMCBAZ-UHFFFAOYSA-L Endothal-disodium Chemical compound [Na+].[Na+].C1CC2C(C([O-])=O)C(C(=O)[O-])C1O2 XRHVZWWRFMCBAZ-UHFFFAOYSA-L 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
206010064571 Gene mutation Diseases 0.000 description 2
108010024636 Glutathione Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
208000026350 Inborn Genetic disease Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
239000012359 Methanesulfonyl chloride Substances 0.000 description 2
108010021466 Mutant Proteins Proteins 0.000 description 2
102000008300 Mutant Proteins Human genes 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
208000012287 Prolapse Diseases 0.000 description 2
239000004365 Protease Substances 0.000 description 2
208000002200 Respiratory Hypersensitivity Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
108090000643 Vasopressin Receptors Proteins 0.000 description 2
102000004136 Vasopressin Receptors Human genes 0.000 description 2
208000005946 Xerostomia Diseases 0.000 description 2
239000002250 absorbent Substances 0.000 description 2
230000002745 absorbent Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
235000010419 agar Nutrition 0.000 description 2
230000010085 airway hyperresponsiveness Effects 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
229940121363 anti-inflammatory agent Drugs 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
229960003644 aztreonam Drugs 0.000 description 2
WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 2
238000003287 bathing Methods 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
229920002988 biodegradable polymer Polymers 0.000 description 2
239000004621 biodegradable polymer Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
235000019437 butane-1,3-diol Nutrition 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
235000005687 corn oil Nutrition 0.000 description 2
239000002285 corn oil Substances 0.000 description 2
235000012343 cottonseed oil Nutrition 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000013480 data collection Methods 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
238000010586 diagram Methods 0.000 description 2
LTMHNWPUDSTBKD-UHFFFAOYSA-N diethyl 2-(ethoxymethylidene)propanedioate Chemical compound CCOC=C(C(=O)OCC)C(=O)OCC LTMHNWPUDSTBKD-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000008298 dragée Substances 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
239000003792 electrolyte Substances 0.000 description 2
238000003372 electrophysiological method Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229940045109 genistein Drugs 0.000 description 2
235000006539 genistein Nutrition 0.000 description 2
ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000009931 harmful effect Effects 0.000 description 2
230000001744 histochemical effect Effects 0.000 description 2
208000000509 infertility Diseases 0.000 description 2
230000036512 infertility Effects 0.000 description 2
231100000535 infertility Toxicity 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
206010023332 keratitis Diseases 0.000 description 2
201000010666 keratoconjunctivitis Diseases 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
UFSKUSARDNFIRC-UHFFFAOYSA-N lumacaftor Chemical compound N1=C(C=2C=C(C=CC=2)C(O)=O)C(C)=CC=C1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 UFSKUSARDNFIRC-UHFFFAOYSA-N 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
239000004530 micro-emulsion Substances 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
238000012856 packing Methods 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
229940045258 pancrelipase Drugs 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
WFIZEGIEIOHZCP-UHFFFAOYSA-M potassium formate Chemical compound [K+].[O-]C=O WFIZEGIEIOHZCP-UHFFFAOYSA-M 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
229960004063 propylene glycol Drugs 0.000 description 2
238000010926 purge Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
210000001533 respiratory mucosa Anatomy 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
201000009881 secretory diarrhea Diseases 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
235000011803 sesame oil Nutrition 0.000 description 2
BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
238000010898 silica gel chromatography Methods 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
239000012258 stirred mixture Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000008719 thickening Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
239000002753 trypsin inhibitor Substances 0.000 description 2
238000001622 two pulse phase modulation pulse sequence Methods 0.000 description 2
238000005303 weighing Methods 0.000 description 2
DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
229940058015 1,3-butylene glycol Drugs 0.000 description 1
KLGOVBORDJMXPN-UHFFFAOYSA-N 1-(trifluoromethyl)-2h-quinoline-3-carboxylic acid Chemical compound C1=CC=C2N(C(F)(F)F)CC(C(=O)O)=CC2=C1 KLGOVBORDJMXPN-UHFFFAOYSA-N 0.000 description 1
YSTPBENEBQWBDT-UHFFFAOYSA-N 1-[4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl]-5-(trifluoromethyl)quinolin-4-one Chemical compound C12CCC(CC1)N2C1=CC(=C(C=C1)N1C=CC(C2=C(C=CC=C12)C(F)(F)F)=O)C(F)(F)F YSTPBENEBQWBDT-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
SDDSJMXGJNWMJY-BRHAQHMBSA-N 7-[(2r,4ar,5r,7ar)-2-[(3s)-1,1-difluoro-3-methylpentyl]-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid Chemical compound O1[C@](C(F)(F)C[C@@H](C)CC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 SDDSJMXGJNWMJY-BRHAQHMBSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
208000010444 Acidosis Diseases 0.000 description 1
206010027654 Allergic conditions Diseases 0.000 description 1
102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
102100026277 Alpha-galactosidase A Human genes 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
102000010637 Aquaporins Human genes 0.000 description 1
108010063290 Aquaporins Proteins 0.000 description 1
235000017060 Arachis glabrata Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
235000010777 Arachis hypogaea Nutrition 0.000 description 1
235000018262 Arachis monticola Nutrition 0.000 description 1
206010003557 Asthma exercise induced Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
206010006448 Bronchiolitis Diseases 0.000 description 1
0 CCC(CCC1)C1Nc(cc1)cc(C(F)(F)F)c1NC(C1=CNc2cccc(C(F)(F)F)c2C1=C)=* Chemical compound CCC(CCC1)C1Nc(cc1)cc(C(F)(F)F)c1NC(C1=CNc2cccc(C(F)(F)F)c2C1=C)=* 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010050389 Cerebral ataxia Diseases 0.000 description 1
208000009043 Chemical Burns Diseases 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
201000002200 Congenital disorder of glycosylation Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
GBNRNAVAZIWIPR-MEZFUOHNSA-N FC(C(=O)O)(F)F.N[C@@H]1CC[C@H](CC1)CS(=O)(=O)O Chemical compound FC(C(=O)O)(F)F.N[C@@H]1CC[C@H](CC1)CS(=O)(=O)O GBNRNAVAZIWIPR-MEZFUOHNSA-N 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102100020948 Growth hormone receptor Human genes 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
241000188250 Idas Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100027612 Kallikrein-11 Human genes 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
208000026709 Liddle syndrome Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000003939 Membrane transport proteins Human genes 0.000 description 1
108090000301 Membrane transport proteins Proteins 0.000 description 1
208000024556 Mendelian disease Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
108700011325 Modifier Genes Proteins 0.000 description 1
102000014842 Multidrug resistance proteins Human genes 0.000 description 1
108050005144 Multidrug resistance proteins Proteins 0.000 description 1
102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
HSVIINWFPKEOEQ-NSHDSACASA-N Ofloxacin methyl ester Chemical compound C([C@H](C)N1C=C(C(C(=C11)C=C2F)=O)C(=O)OC)OC1=C2N1CCN(C)CC1 HSVIINWFPKEOEQ-NSHDSACASA-N 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
102100035917 Peripheral myelin protein 22 Human genes 0.000 description 1
101710199257 Peripheral myelin protein 22 Proteins 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
QSXMZJGGEWYVCN-UHFFFAOYSA-N Pirbuterol acetate Chemical compound CC(O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 QSXMZJGGEWYVCN-UHFFFAOYSA-N 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
108010050808 Procollagen Proteins 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
208000015815 Rectal disease Diseases 0.000 description 1
108700005075 Regulator Genes Proteins 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
108010000303 Secretory Proteinase Inhibitory Proteins Proteins 0.000 description 1
102000002255 Secretory Proteinase Inhibitory Proteins Human genes 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
108010068542 Somatotropin Receptors Proteins 0.000 description 1
SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
241001415849 Strigiformes Species 0.000 description 1
241000272534 Struthio camelus Species 0.000 description 1
102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
201000009594 Systemic Scleroderma Diseases 0.000 description 1
206010042953 Systemic sclerosis Diseases 0.000 description 1
206010053615 Thermal burn Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
101710152431 Trypsin-like protease Proteins 0.000 description 1
102000003425 Tyrosinase Human genes 0.000 description 1
108060008724 Tyrosinase Proteins 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010046377 Whey Proteins Proteins 0.000 description 1
SVJGGWZOTSJMCQ-RMTIMQEASA-N [(1s,2s,3r,4r,5s,6r)-2,3,4,5-tetrakis[bis(propanoyloxymethoxy)phosphoryloxy]-6-octoxycyclohexyl] butanoate Chemical compound CCCCCCCCO[C@@H]1[C@H](OC(=O)CCC)[C@H](OP(=O)(OCOC(=O)CC)OCOC(=O)CC)[C@@H](OP(=O)(OCOC(=O)CC)OCOC(=O)CC)[C@H](OP(=O)(OCOC(=O)CC)OCOC(=O)CC)[C@H]1OP(=O)(OCOC(=O)CC)OCOC(=O)CC SVJGGWZOTSJMCQ-RMTIMQEASA-N 0.000 description 1
239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
239000003655 absorption accelerator Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000007950 acidosis Effects 0.000 description 1
208000026545 acidosis disease Diseases 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000009056 active transport Effects 0.000 description 1
201000009840 acute diarrhea Diseases 0.000 description 1
239000008272 agar Substances 0.000 description 1
210000001552 airway epithelial cell Anatomy 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
201000009961 allergic asthma Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
108010091628 alpha 1-Antichymotrypsin Proteins 0.000 description 1
108010030291 alpha-Galactosidase Proteins 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
229960004821 amikacin Drugs 0.000 description 1
LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
229960002576 amiloride Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
229960003995 ataluren Drugs 0.000 description 1
229960004099 azithromycin Drugs 0.000 description 1
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 1
108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
230000003435 bronchoconstrictive effect Effects 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
XASIMHXSUQUHLV-UHFFFAOYSA-N camostat Chemical compound C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C(N=C(N)N)C=C1 XASIMHXSUQUHLV-UHFFFAOYSA-N 0.000 description 1
229960000772 camostat Drugs 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
AQWKVJFRGORALM-UHFFFAOYSA-N chembl1941089 Chemical compound CC1=CC=C(O)C(C2=NNC(=C2)C=2C=CC=CC=2)=C1 AQWKVJFRGORALM-UHFFFAOYSA-N 0.000 description 1
229910052729 chemical element Inorganic materials 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
150000003841 chloride salts Chemical class 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
208000019902 chronic diarrheal disease Diseases 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
229960003405 ciprofloxacin Drugs 0.000 description 1
239000004927 clay Substances 0.000 description 1
229950005980 cobiprostone Drugs 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000010835 comparative analysis Methods 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
229940092125 creon Drugs 0.000 description 1
238000005388 cross polarization Methods 0.000 description 1
238000005384 cross polarization magic-angle spinning Methods 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
238000002447 crystallographic data Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
238000013500 data storage Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
239000000645 desinfectant Substances 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
125000004431 deuterium atom Chemical group 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
235000019797 dipotassium phosphate Nutrition 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000004821 distillation Methods 0.000 description 1
230000035619 diuresis Effects 0.000 description 1
235000020669 docosahexaenoic acid Nutrition 0.000 description 1
KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
108010067396 dornase alfa Proteins 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000003221 ear drop Substances 0.000 description 1
229940047652 ear drops Drugs 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
208000030172 endocrine system disease Diseases 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000002713 epithelial sodium channel blocking agent Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
229940093499 ethyl acetate Drugs 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
239000003172 expectorant agent Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
ZHPNWZCWUUJAJC-UHFFFAOYSA-N fluorosilicon Chemical compound [Si]F ZHPNWZCWUUJAJC-UHFFFAOYSA-N 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
238000004508 fractional distillation Methods 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
239000003517 fume Substances 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N hexane carboxylic acid Natural products CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000003906 humectant Substances 0.000 description 1
230000000887 hydrating effect Effects 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
229960004171 hydroxychloroquine Drugs 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000021267 infertility disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
208000003243 intestinal obstruction Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000003591 leukocyte elastase inhibitor Substances 0.000 description 1
239000012035 limiting reagent Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000004807 localization Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
108010082117 matrigel Proteins 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000000155 melt Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
229940066491 mucolytics Drugs 0.000 description 1
108010066052 multidrug resistance-associated protein 1 Proteins 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
230000008518 non respiratory effect Effects 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
208000007892 occupational asthma Diseases 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
229940041678 oral spray Drugs 0.000 description 1
239000000668 oral spray Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
235000020232 peanut Nutrition 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
229960005095 pioglitazone Drugs 0.000 description 1
229960004994 pirbuterol acetate Drugs 0.000 description 1
230000010287 polarization Effects 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
239000004632 polycaprolactone Substances 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Chemical class 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000008569 process Effects 0.000 description 1
229950008679 protamine sulfate Drugs 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000012846 protein folding Effects 0.000 description 1
238000001799 protein solubilization Methods 0.000 description 1
230000007925 protein solubilization Effects 0.000 description 1
230000009325 pulmonary function Effects 0.000 description 1
229940107568 pulmozyme Drugs 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
208000020029 respiratory tract infectious disease Diseases 0.000 description 1
239000003340 retarding agent Substances 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
229960004017 salmeterol Drugs 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
230000011664 signaling Effects 0.000 description 1
229960003310 sildenafil Drugs 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000002356 single layer Substances 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
229910052665 sodalite Inorganic materials 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000000176 sodium gluconate Substances 0.000 description 1
235000012207 sodium gluconate Nutrition 0.000 description 1
229940005574 sodium gluconate Drugs 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
229940075554 sorbate Drugs 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000005469 synchrotron radiation Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000002278 tabletting lubricant Substances 0.000 description 1
ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 1
JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
PASYJVRFGUDDEW-WMUGRWSXSA-J tetrasodium;[[(2r,3s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)[C@@H](O)C1 PASYJVRFGUDDEW-WMUGRWSXSA-J 0.000 description 1
230000036575 thermal burns Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
229940054369 ultrase Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000010497 wheat germ oil Substances 0.000 description 1
235000021119 whey protein Nutrition 0.000 description 1
239000002676 xenobiotic agent Substances 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Immunology (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Otolaryngology (AREA)
Dermatology (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)

RU2012121168/04A 2009-10-23 2010-10-21 Твердые формы n-(4-(7-азабицикло[2.2.1]гептан-7-ил)-2-(трифторметил)фенил)-4-оксо-5-(трифторметил)-1,4-дигидрохинолин-3-карбоксамида RU2568608C2 (ru)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US25461409P	2009-10-23	2009-10-23
US61/254,614		2009-10-23
PCT/US2010/053633 WO2011050220A1 (en)	2009-10-23	2010-10-21	Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide

Publications (2)

Publication Number	Publication Date
RU2012121168A RU2012121168A (ru)	2013-11-27
RU2568608C2 true RU2568608C2 (ru)	2015-11-20

Family

ID=43334525

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2012121168/04A RU2568608C2 (ru)	2009-10-23	2010-10-21	Твердые формы n-(4-(7-азабицикло[2.2.1]гептан-7-ил)-2-(трифторметил)фенил)-4-оксо-5-(трифторметил)-1,4-дигидрохинолин-3-карбоксамида

Country Status (18)

Country	Link
US (2)	US8389727B2 (2)
EP (1)	EP2491042A1 (2)
JP (1)	JP5877157B2 (2)
KR (1)	KR20120102645A (2)
CN (1)	CN102666546B (2)
AR (1)	AR078766A1 (2)
AU (1)	AU2010310617A1 (2)
BR (1)	BR112012009584A2 (2)
CA (1)	CA2778493A1 (2)
CL (1)	CL2012001007A1 (2)
IL (1)	IL219327A0 (2)
MX (1)	MX2012004791A (2)
NZ (1)	NZ599703A (2)
RU (1)	RU2568608C2 (2)
TW (1)	TWI507409B (2)
UA (1)	UA108087C2 (2)
WO (1)	WO2011050220A1 (2)
ZA (1)	ZA201202919B (2)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA200602755B (en)	2003-09-06	2007-06-27	Vertex Pharma	Modulators of ATP-binding cassette transporters
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
LT2502911T (lt)	2004-06-24	2017-09-11	Vertex Pharmaceuticals Incorporated	Atp surišančios kasetės transporterių moduliatoriai
ATE512145T1 (de)	2005-08-11	2011-06-15	Vertex Pharma	Modulatoren des cystic fibrosis transmembrane conductance regulators
EP1945632B1 (en)	2005-11-08	2013-09-18	Vertex Pharmaceuticals Incorporated	Heterocyclic modulators of atp-binding cassette transporters
AU2006336504C9 (en)	2005-12-28	2015-05-14	Vertex Pharmaceuticals Incorporated	1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
WO2007079139A2 (en)	2005-12-28	2007-07-12	Vertex Pharmaceuticals, Inc.	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
NZ571803A (en)	2006-04-07	2011-12-22	Vertex Pharma	Amide indole derivatives as modulators of ATP-binding cassette transporters
US8563573B2 (en) *	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
US8969386B2 (en)	2007-05-09	2015-03-03	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
HUE028426T2 (en)	2007-08-24	2016-12-28	Vertex Pharma	Isothiazolopyridinones for (inter alia) treating cystic fibrosis
SI2217572T1 (sl)	2007-11-16	2014-05-30	Vertex Pharmaceuticals Incorporated	Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto
SI2225230T1 (sl)	2007-12-07	2017-03-31	Vertex Pharmaceuticals Incorporated	Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
EP2639224B1 (en)	2007-12-07	2016-08-24	Vertex Pharmaceuticals Incorporated	Process for producing cycloalkylcarboxiamido-pyridine benzoic acids
WO2009076141A2 (en) *	2007-12-07	2009-06-18	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cycklopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
NZ720282A (en)	2008-02-28	2017-12-22	Vertex Pharma	Heteroaryl derivatives as cftr modulators
EP2271621B1 (en)	2008-03-31	2013-11-20	Vertex Pharmaceuticals Incorporated	Pyridyl derivatives as cftr modulators
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
JP2012504143A (ja) *	2008-09-29	2012-02-16	バーテックスファーマシューティカルズインコーポレイテッド	３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の用量単位
NZ592685A (en) *	2008-10-23	2013-04-26	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
PT2358680E (pt) *	2008-10-23	2013-05-14	Vertex Pharma	Formas sólidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2- (trifluorometil)fenil)-4-oxo- 5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida
SI2408750T1 (sl)	2009-03-20	2015-11-30	Vertex Pharmaceuticals Incorporated	Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
BR112012006031A2 (pt) *	2009-09-17	2019-09-24	Vertex Pharma	processo para preparação de compostos azabicíclicos.
WO2011050220A1 (en) *	2009-10-23	2011-04-28	Vertex Pharmaceuticals Incorporated	Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
CN102648182A (zh) *	2009-10-23	2012-08-22	沃泰克斯药物股份有限公司	用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
HRP20211752T1 (hr)	2010-04-07	2022-02-18	Vertex Pharmaceuticals Incorporated	Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
HRP20160682T1 (hr)	2010-04-07	2016-07-29	Vertex Pharmaceuticals Incorporated	Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline
ES2608474T3 (es)	2010-04-22	2017-04-11	Vertex Pharmaceuticals Incorporated	Proceso de producción de compuestos indol cycloalkylcarboxamido
TW201202250A (en) *	2010-05-20	2012-01-16	Vertex Pharma	Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
IN2014KN00885A (2)	2011-11-08	2015-10-02	Vertex Pharma
WO2013112804A1 (en)	2012-01-25	2013-08-01	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2819670A1 (en)	2012-02-27	2015-01-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administration thereof
US8674108B2 (en)	2012-04-20	2014-03-18	Vertex Pharmaceuticals Incorporated	Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2014014841A1 (en)	2012-07-16	2014-01-23	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
JP6963896B2 (ja)	2013-11-12	2021-11-10	バーテックスファーマシューティカルズインコーポレイテッドVertex Pharmaceuticals Incorporated	Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
ES2885181T3 (es)	2014-04-15	2021-12-13	Vertex Pharma	Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
KR20170063954A (ko)	2014-10-07	2017-06-08	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
PT3221692T (pt)	2014-11-18	2021-09-10	Vertex Pharma	Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US12324802B2 (en)	2020-11-18	2025-06-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2155754C2 (ru) *	1994-05-27	2000-09-10	Смитклайн Бичам С.П.А.	Производные хинолина как антагонисты nk3-рецептора тахикинина

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5886026A (en)	1993-07-19	1999-03-23	Angiotech Pharmaceuticals Inc.	Anti-angiogenic compositions and methods of use
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
LT2502911T (lt) *	2004-06-24	2017-09-11	Vertex Pharmaceuticals Incorporated	Atp surišančios kasetės transporterių moduliatoriai
WO2007079139A2 (en)	2005-12-28	2007-07-12	Vertex Pharmaceuticals, Inc.	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CL2008003651A1 (es)	2007-12-10	2009-06-19	Novartis Ag	Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
NZ592685A (en) *	2008-10-23	2013-04-26	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
PT2358680E (pt) *	2008-10-23	2013-05-14	Vertex Pharma	Formas sólidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2- (trifluorometil)fenil)-4-oxo- 5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida
US20110257223A1 (en) *	2008-10-23	2011-10-20	Vertex Pharmaceuticals Incorporated	Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
CN102648182A (zh) *	2009-10-23	2012-08-22	沃泰克斯药物股份有限公司	用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
WO2011050220A1 (en) *	2009-10-23	2011-04-28	Vertex Pharmaceuticals Incorporated	Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide

2010
- 2010-10-21 WO PCT/US2010/053633 patent/WO2011050220A1/en not_active Ceased
- 2010-10-21 CN CN201080053379.2A patent/CN102666546B/zh not_active Expired - Fee Related
- 2010-10-21 KR KR1020127013139A patent/KR20120102645A/ko not_active Withdrawn
- 2010-10-21 AU AU2010310617A patent/AU2010310617A1/en not_active Abandoned
- 2010-10-21 JP JP2012535394A patent/JP5877157B2/ja not_active Expired - Fee Related
- 2010-10-21 MX MX2012004791A patent/MX2012004791A/es active IP Right Grant
- 2010-10-21 UA UAA201206183A patent/UA108087C2/uk unknown
- 2010-10-21 EP EP10774360A patent/EP2491042A1/en not_active Withdrawn
- 2010-10-21 US US12/909,789 patent/US8389727B2/en active Active
- 2010-10-21 RU RU2012121168/04A patent/RU2568608C2/ru not_active IP Right Cessation
- 2010-10-21 CA CA2778493A patent/CA2778493A1/en not_active Abandoned
- 2010-10-21 BR BR112012009584A patent/BR112012009584A2/pt not_active IP Right Cessation
- 2010-10-21 NZ NZ599703A patent/NZ599703A/en not_active IP Right Cessation
- 2010-10-22 TW TW099136177A patent/TWI507409B/zh not_active IP Right Cessation
- 2010-10-25 AR ARP100103915A patent/AR078766A1/es unknown
2012
- 2012-04-20 CL CL2012001007A patent/CL2012001007A1/es unknown
- 2012-04-20 ZA ZA2012/02919A patent/ZA201202919B/en unknown
- 2012-04-22 IL IL219327A patent/IL219327A0/en unknown
2013
- 2013-01-28 US US13/751,656 patent/US8741922B2/en active Active

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2155754C2 (ru) *	1994-05-27	2000-09-10	Смитклайн Бичам С.П.А.	Производные хинолина как антагонисты nk3-рецептора тахикинина

Also Published As

Publication number	Publication date
TWI507409B (zh)	2015-11-11
JP2013508407A (ja)	2013-03-07
CA2778493A1 (en)	2011-04-28
AR078766A1 (es)	2011-11-30
WO2011050220A1 (en)	2011-04-28
HK1173151A1 (zh)	2013-07-05
NZ599703A (en)	2014-06-27
CL2012001007A1 (es)	2012-09-07
BR112012009584A2 (pt)	2019-09-24
US8741922B2 (en)	2014-06-03
EP2491042A1 (en)	2012-08-29
US20110123449A1 (en)	2011-05-26
ZA201202919B (en)	2013-06-26
US20130137722A1 (en)	2013-05-30
KR20120102645A (ko)	2012-09-18
AU2010310617A1 (en)	2012-05-24
UA108087C2 (uk)	2015-03-25
CN102666546B (zh)	2015-09-09
US8389727B2 (en)	2013-03-05
TW201121976A (en)	2011-07-01
CN102666546A (zh)	2012-09-12
JP5877157B2 (ja)	2016-03-02
RU2012121168A (ru)	2013-11-27
IL219327A0 (en)	2012-06-28
MX2012004791A (es)	2013-02-01

Legal Events

Date	Code	Title	Description
2017-07-13	MM4A	The patent is invalid due to non-payment of fees	Effective date: 20161022

Publication	Publication Date	Title
RU2568608C2 (ru)	2015-11-20	Твердые формы n-(4-(7-азабицикло[2.2.1]гептан-7-ил)-2-(трифторметил)фенил)-4-оксо-5-(трифторметил)-1,4-дигидрохинолин-3-карбоксамида
RU2553989C2 (ru)	2015-06-20	Способ получения модуляторов регулятора трансмембранной проводимости кистозного фиброза
CN102224141B (zh)	2014-10-08	N-(4-(7-氮杂双环[2.2.1]庚-7-基)-2-(三氟甲基)苯基)-4-氧代-5-(三氟甲基)-1,4-二氢喹啉-3-甲酰胺的固体形式
HK1173151B (en)	2016-09-02	Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
HK1173150A (en)	2013-05-10	Process for preparing modulators of cystic fibrosis transmembrane conductance regulator
HK1158650B (en)	2015-09-11	Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide